

537,401

(12) INTERNATIONAL PUBLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

02 JUN 2005

(43) International Publication Date
17 June 2004 (17.06.2004)

PCT

(10) International Publication Number
WO 2004/049830 A1(51) International Patent Classification⁷: **A23L 1/305,**
2/66, A61K 38/04, 38/17(JP). KOMATSU, Miho [JP/JP]; c/o Tsukuba Research
Laboratories, Kyowa Hakko Kogyo Co., Ltd., 2, Miyuki-
gaoka, Tsukuba-shi, Ibaraki 305-0841 (JP).

(21) International Application Number:

PCT/JP2003/015429

(74) Agents: OGURI, Shohei et al.; Eikoh Patent Office, ARK
Mori Building, 13th Floor, 12-32, Akasaka 1-chome, Mi-
nato-ku, Tokyo 107-6013 (JP).

(22) International Filing Date: 2 December 2003 (02.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2002-350200

2 December 2002 (02.12.2002) JP

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(71) Applicants (*for all designated States except US*): MELJI
DAIRIES CORPORATION [JP/JP]; 2-10, Shinsuna
1-chome, Koto-ku, Tokyo 136-8908 (JP). KYOWA
HAKKO KOGYO CO., LTD. [JP/JP]; 6-1, Ohtemachi
1-chome, Chiyoda-ku, Tokyo 100-8185 (JP).(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): TSUCHITA, Hi-
roshi [JP/JP]; c/o Nutrition Science Institute, Meiji Dairies
Corporation, 540, Naruda, Odawara-shi, Kanagawa
250-0862 (JP). SAITO, Masato [JP/JP]; c/o Nutrition
Science Institute, Meiji Dairies Corporation, 540, Naruda,
Odawara-shi, Kanagawa 250-0862 (JP). KAMIYA,
Toshikazu [JP/JP]; c/o Kyowa Hakko Kogyo Co., Ltd.,
6-1 Ohtemachi 1-chome, Chiyoda-ku, Tokyo 100-8185

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUSTAINED IMPROVER OF MUSCULAR FATIGUE

(57) Abstract: A long-acting improver of muscular fatigue characterized by comprising 4 kinds of amino acids made up of leucine, isoleucine, valine and glutamine, and a whey protein component (whey protein and/or decomposition product of whey protein). At least one of a whey protein isolate (WPI), a whey protein concentrate (WPC), β -lactoglobulin, and α -lactalbumin is used as the whey protein. Novel food or drink, and pharmaceuticals which exhibit sustained recovery effects on muscular fatigue are provided.

WO 2004/049830 A1

DESCRIPTION

SUSTAINED IMPROVER OF MUSCULAR FATIGUE

Technical Field

The present invention relates to a sustained improver of muscular fatigue or food or drink for sustained improvement of muscular fatigue which comprises amino acids and a whey protein component.

Background Art

Leucine, isoleucine and valine are called branched chain amino acids (BCAA) and a mixture of these three kinds of amino acids is known to have muscular fatigue recovery effect (e.g., see JP-A-8-198748). The mixture of the three kinds of BCAA has been widely used as nutrients by being made into granules or drinks, but immediately after being absorbed to the small intestine, it is relatively rapidly metabolized, and thus sustained effect on muscular fatigue recovery is unlikely obtained.

Also, nutrients comprising a whey protein or a decomposition product of whey protein or soy protein have been known, but no sustained action on muscular fatigue recovery has been known (e.g., see *Gastroenterology*, 7, 151-161 (1976) and *Gut*, 14, 494-501 (1974)).

On the other hand, as a mixed composition of the mixture of the three kinds of amino acids with a protein, a composition obtained by adding to an amino acid mixture of leucine, isoleucine and valine 2- to 30-fold amounts of a protein, followed by solidification, is also known (e.g., see JP-A-60-186261), but the protein is used only as an excipient and is not used for facilitating fatigue recovery effects.

Disclosure of the Invention

It has been accepted that a nutrient comprising the BCAA mixture used for sports is taken once a day in the form of jelly or granules of about 2 to 3 g. Such administration is highly effective immediately after the administration, but it does not show sustained effect, because the amino acids in blood are metabolized and excreted gradually. Therefore, nutrient compositions having sustained effect on muscular fatigue recovery suitable for the administration method with once a day have been desired. Of course, it is the same in intended uses, for example for health care, health maintenance, and recovery of fatigue in daily life in addition to sports.

The present invention has been performed for the purpose of responding to the above requests in the art, the present inventors have studied widely from various aspects, taken note of necessity to formulate the other components to BCAA for the first time, and not only taken note of amino acids in numerous various components but also found necessity to formulate different components from the amino acids. And, the present inventors have taken note of glutamine in numerous amino acids and for the first time have taken note of whey protein components as the other components.

Thus, the present inventors have formulated glutamine and whey protein components in the BCAA mixture for a formulated composition of the BCAA mixture, then as a result of intensive study of the composition, have discovered that recovery effect of muscular fatigue is sustained, and have completed the present invention.

The present invention relates to the following (1) to (16).

- (1) A sustained improver of muscular fatigue, which consists of leucine, isoleucine, valine, glutamine and a whey protein component.
- (2) A sustained improver of muscular fatigue, which comprises, as active ingredients, leucine, isoleucine, valine, glutamine and a whey protein component.
- (3) The improver according to (1) or (2), wherein the whey protein component is whey protein and/or a decomposition product of whey protein.

- (4) The improver according to (3), wherein the whey protein is at least one selected from the group consisting of a whey protein isolate, a whey protein concentrate, β -lactoglobulin, and α -lactalbumin.
- (5) The improver according to any one of (1) to (4), which comprises leucine in an amount of 10 to 30 parts by weight, isoleucine in an amount of 5 to 15 parts by weight, valine in an amount of 5 to 15 parts by weight, glutamine in an amount of 5 to 15 parts by weight, and the whey protein component in an amount of 75 to 25 weight.
- (6) The improver according to any one of (1) to (5), which comprises leucine in an amount of 20 parts by weight, isoleucine in an amount of 10 parts by weight, valine in an amount of 10 parts by weight, glutamine in an amount of 10 parts by weight, and the whey protein component in an amount of 50 parts by weight.
- (7) The improver according to (6), wherein the whey protein component is a decomposition product of whey protein.
- (8) A food or drink for sustained improvement of muscular fatigue, which comprises, as an active ingredients, leucine, isoleucine, valine, glutamine and a whey protein component.
- (9) The food or drink according to (8), wherein the whey protein component is whey protein and/or a decomposition product of whey protein.
- (10) The food or drink according to (9), wherein the whey protein is at least one selected from the group consisting of a whey protein isolate, a whey protein concentrate, β -lactoglobulin, and α -lactalbumin.
- (11) The food or drink according to any one of (8) to (10), which comprises leucine in an amount of 10 to 30 parts by weight, isoleucine in an amount of 5 to 15 parts by weight, valine in an amount of 5 to 15 parts by weight, glutamine in an amount of 5 to 15 parts by weight, and the whey protein component in an amount of 75 to 25 parts by weight.

- (12) The food or drink according to any one of (8) to (11), which comprises leucine in an amount of 20 parts by weight, isoleucine in an amount of 10 parts by weight, valine in an amount of 10 parts by weight, glutamine in an amount of 10 parts by weight, and the whey protein component in an amount of 50 parts by weight.
- (13) The food or drink according to (12), wherein the whey protein component is a decomposition product of whey protein.
- (14) The use of leucine, isoleucine, valine, glutamine and a whey protein component for the manufacture of a sustained improver of muscular fatigue.
- (15) The use of leucine, isoleucine, valine, glutamine and a whey protein component for the manufacture of food or drink for sustained improvement of muscular fatigue.
- (16) A method of improving muscular fatigue sustainably, which comprises administering leucine, isoleucine, valine, glutamine and a whey protein component.

The present invention relates to a sustained improver of muscular fatigue which comprises leucine, isoleucine, valine, glutamine and a whey protein component. Since the present invention can be utilized as any of pharmaceuticals, foods and drinks, the present invention can provide sustained improvers of muscular fatigue or foods or drinks for the sustained improvement of muscular fatigue.

The present invention relates to the sustained improver of muscular fatigue or the food or drink comprising the above 4 kinds of the amino acids and the whey protein component, but includes any of the improvers or foods or drinks comprising them as active ingredients and the agents consisting of them.

In the sustained improvers of muscular fatigue or foods or drinks comprising 4 kinds of the amino acids and the whey protein component as active ingredients, generally, 4 kinds of the amino acids should be present independently as respective amino acid compounds, and the other amino acids, components of sustained

improvers of muscular fatigue, foods or drinks, peptides and the like can be combined. Also, when a content of each amino acid of 4 kinds of the amino acids is known, mixtures or ingredients (e.g., peptides, decomposition products of peptides, foods, *etc.*) thereof which are not pure amino acids can be used. Furthermore, it is possible to combine the pure amino acids and the mixtures thereof at the desired ratio. Also, as for the whey protein components, it is similarly possible to use pure components or the ingredients (mixtures) thereof.

In the sustained improvers of muscular fatigue consisting of 4 kinds of the amino acids and the whey protein component, as 4 kinds of the amino acids, only 4 kinds of pure amino acid compounds are used, and the other amino acids, peptides, decomposition products of peptides, foods or drinks and the other components of sustained improvers of muscular fatigue are not combined. It is also the same for the whey protein components.

That is, the present invention includes both the improvers which consist of 4 kinds of the pure amino acids and the whey protein component and does not comprise the other components of sustained improvers of muscular fatigue, and the improvers or foods or drinks which contain them as active ingredients. Of course, in the former case, it is not prevented to use aids needed to preparations and water for making drinks, which are not the components of sustained improvers of muscular fatigue.

In the present invention, the whey protein and/or the decomposition product of whey protein is used as the whey protein component. The whey protein includes a whey protein isolate (WPI), a whey protein concentrate (WPC), an α -lactalbumin concentrate and a β -lactoglobulin concentrate, and the decomposition product of whey protein includes hydrolysate thereof. They are used alone or in combination of two or more.

WPCs are those where the whey produced at the production of cheese and casein is treated by methods such as ultrafiltration, gel filtration and lactose crystal

separation to raise a protein content therein generally up to from 35 to 85% (as solid content).

WPI is different from WPC, and its protein content is raised up to about 95% (as solid content) by the method such as an ion exchange method.

The α -lactalbumin concentrate and the β -lactoglobulin concentrate can be obtained from WPI and WPC by fractionating and concentrating by the methods known in the art described in JP-B-3-60468.

The hydrolysate may be any peptides as long as they are obtained by the methods in the art, e.g., the method for obtaining by hydrolyzing with a protease derived from *Bacillus*, a protease derived from *Actinomyces*, trypsin, chymotrypsin and the like as described in JP-A-6-343422, and are generally used for foods or drinks.

Also, the whey protein component may be not only the whey protein alone or the decomposition product of whey protein alone but also a mixture of both, and the decomposition product of whey protein is preferably used as the component.

A composition ratio of leucine, isoleucine, valine, glutamine and the whey protein component of the present invention includes leucine at 10 to 30 parts by weight, isoleucine at 5 to 15 parts by weight, valine at 5 to 15 parts by weight, glutamine at 5 to 15 parts by weight and the whey protein component at 75 to 25 parts by weight, preferably leucine at 16 to 24 parts by weight, isoleucine at 8 to 12 parts by weight, valine at 8 to 12 parts by weight, glutamine at 8 to 12 parts by weight and the whey protein component at 60 to 40 parts by weight, and most preferably leucine at 20 parts by weight, isoleucine at 10 parts by weight, valine at 10 parts by weight, glutamine at 10 parts by weight and the whey protein component (e.g., decomposition product of whey protein) at 50 parts by weight. Also, the composition ratio of leucine, isoleucine, valine and glutamine with the whey protein component includes leucine, isoleucine, valine and glutamine at 25 to 75 parts by weight and the whey protein component at 75 to 25 parts by weight, preferably leucine, isoleucine, valine and glutamine at 40 to 60

parts by weight and the 60 to 40 parts by weight of the whey protein component, and most preferably leucine, isoleucine, valine and glutamine at 50 parts by weight and the whey protein component at 50 parts by weight.

Besides, the parts by weight of the whey protein component are referred to net weight of whey protein or decomposition product of whey protein contained in the whey protein component such as WPI and WPC (the same hereinafter).

In the present invention, the sustained improver of muscular fatigue or the food or drink for the sustained improvement of muscular fatigue may be any of those as long as they are pharmaceuticals or foods or drinks which can be used for the prevention or the treatment of muscular fatigue.

Kinds of foods or drinks can exemplify nutrient compositions such as tablets, capsules and liquid formations sold as healthy foods (including foods for specified health use, nutrient functional foods, foods or drinks for sports, and the like), juices, soft drinks, teas, lactic acid bacteria beverages, fermented milk, milk products (processed milk, skim milk and the like), snacks (candy, drops, chocolate, jelly, biscuit, cookie, ice cream, *etc.*). In the case of anticipating the recovery effect of muscular fatigue, it is preferred that it is orally used as the healthy food comprising effective amounts of leucine, isoleucine, valine and glutamine and a whey protein component. In the case of using as the pharmaceutical, for example, also preferred are oral agents such as tablets, capsules, syrup, and sublingual tablets.

Therefore, the foods or drinks for the sustained improvement of muscular fatigue include all the above foods or drinks. Also, the improver of the present invention include all of those formulated in the above usual foods or drinks in addition to those formulated into tablets, capsules, liquid formulation and the like and those formulated into dosage forms similar to pharmaceuticals such as supplements and drinks. The pharmaceuticals include all of those formulated into the pharmaceuticals according to the standard methods.

Generally known methods are applied for the formulation of the dosage forms orally administered as the healthy food or the pharmaceutical, and for example, various excipients, lubricants, binders, disintegrants, suspending agents, isotonic agents, emulsifiers and the like may be contained.

Carriers used for the formulation include, for example, water, injectable distilled water, saline, glucose, sucrose, mannite, lactose, mannitol, sorbitol, lactitol, xylitol, erythritol, starch, cellulose, methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, alginic acid, talc, citric acid, calcium carbonate, calcium hydrogen phosphate, magnesium stearate, urea, silicone resin, sorbitan fatty acid ester, glycerate ester and the like.

Leucine, isoleucine, valine, glutamine and the whey protein component in the present invention can be contained at 1 to 1000 mg, preferably from 10 to 900 mg, and most preferably from 100 to 800 mg, per g of the preparation or the food or drink.

Ingestion amount and frequency are different depending on administration route, form, age, body weight, condition and the like, but as 4 kinds of the amino acids and the whey protein component, generally the oral amount is from 0.5 to 4 g, preferably from 1 to 3 g and most preferably from 2 to 3 g. For example, for the tablet containing 500 mg of leucine, isoleucine, valine, glutamine and the whey protein component, it is preferable to ingest 2 to 3 tablets twice a day. Besides, 4 kinds of the amino acids and the decomposition product of whey protein (AAs +P described below) were orally administered at 0.5 g per 100 g of body weight (10-weeks old SD male rats) once a day, and after a month, no death case was observed.

The preparation method when the present invention is used for foods or drinks other than the healthy foods is the same as that of usual foods or drinks except that leucine, isoleucine, valine, glutamine and the whey protein component are added. For example, the drinks can be prepared by dissolving leucine, isoleucine, valine, glutamine and the whey protein component and various additives in an appropriate

amount of water, if necessary. Also, as the foods, for example, snacks such as candy, drops, chocolate, jelly, biscuit and cookie can be prepared by adding leucine, isoleucine, valine, glutamine and the whey protein component, using necessary additives and further appropriate carrier, e.g., wheat, rice powder, starch, corn starch, soy beans and the like and forming into appropriate forms according to the standard methods.

Hereinafter, the present invention is specifically explained below based on Test Example showing the prevention or improvement effects of muscular fatigue of the composition (hereinafter, may also be referred to as KAAM) in which leucine, isoleucine, valine, glutamine and the whey protein component are added, and Examples showing formulation examples of the preventive or therapeutic pharmaceuticals as sustained improvers of muscular fatigue, foods or drinks of the present invention, but the invention is not limited to these specific examples.

Best Mode for Carrying Out the Invention

Test Example 1

Effects of KAAM on muscular proteolysis after exercise:

Three-weeks old SD male rats were used by dividing into the following 3 groups (n=15). Distilled water was orally administered at 30 ml per kg of body weight to the rats in Vehicle group. A mixture solution of leucine, isoleucine, valine, and glutamine (weight ratio of 2:1:1:1) was prepared (a mixture concentration is 1 g per 30 ml of distilled water), and it was orally administered at 30 ml per kg of body weight to the rats in AAs group (an administered amount as the mixture is 1 g per kg of body weight). A mixture solution of leucine, isoleucine, valine, glutamine and the whey protein component (weight ratio of 2:1:1:1:5) was prepared (a mixture concentration is 1 g per 30 ml of distilled water), and it was orally administered at 30 ml per kg of body weight to the rats in AAs + P group (an administered amount as the mixture is 1 g per kg of body weight).

As the decomposition product of whey protein, one produced by the following method was used.

WPI (protein content 92%) (1,000 g) was dissolved in 8,800 g of water. Biopraxe (manufactured by Nagase Biochemical Ltd.) (2,200 units per g of protein), 1,300 units per g of protein of trypsin (manufactured by Novo), 90 units per g of protein of chymotrypsin (manufactured by Novo) and 1,100 units per g of protein of actinase (manufactured by Kaken Pharmaceutical Co., Ltd.) were added, and hydrolyzed at 50°C for 20 hours while adjusting pH at 7.5 with 10% sodium hydroxide solution. The resulting mixture was ultrafiltered by an ultrafiltration filter with a fractionation molecular weight of 20,000 to eliminate the enzymes and insoluble hydrolysate. Further, the solution was desalted until an electric conductivity became 1/10 using an electro dialyzer and then dried to yield the decomposition product of whey protein (content of decomposition product of protein: 94%).

The rats in 3 groups were raised precedently for 3 days, and then an exercise (slope 6 degree, speed 7 to 25 m/min, 30 min) was given once a day for 3 days to familiarize a treadmill. After 18 hours of fasting and 1 hour of cessation of water drinking, the treadmill exercise (slope 6 degree, speed 15 to 30 m/min, 30 min) was given for one hour. Immediately after the exercise, the above distilled water, the amino acid mixture solution or the amino acid and decomposition product of whey protein mixture solution (30 ml per kg of body weight, as the administered amount of mixture, 1 g/kg of body weight) was orally administered to each group, 5 rats in each group was anatomized 6 hours after the administration, musculus soleus was removed from both legs, and it was incubated in Krebs-Henseleit bicarbonate buffer under a gas flow of 95% CO₂-5% O₂ for 2 and a half hours. Tyr (tyrosine) release rate can be used as an index of a degradation rate of musculus soleus cytoplasmic protein. Thus, concentration of Tyr in the buffer was measured to determine Try release rate. On the other hand, apart from the above 3 groups, according to the similar method as that of the

above 3 groups except that the exercise and administration were not carried out, Tyr release rate at 0 hour was measured. The Tyr release rate at 0 hour was used as the Tyr release rate in a non-exercise group.

The Tyr release rates in the non-exercise group, Vehicle group, AAs group and AAs + P group are shown in Table 1.

Table 1

	Hours after administration	Tyr (nmol/g tissue/2h)	p-Value for Vehicle
non-exercise group	No administration	346 \pm 65	---
Vehicle group	After 6 hours	399 \pm 63	---
AAs group	After 6 hours	358 \pm 83	0.3998
AAs + P group	After 6 hours	293 \pm 71*	0.0359

* There is a significant difference between Vehicle group ($p < 0.05$).

As a result, as shown in Table 1, the Tyr release rate from musculus soleus which is an index of the decomposition rate of musculus cytoplasmic serous protein was significantly reduced in AAs + P group compared to Vehicle group (Student's t-test, p-value < 0.05), but there was no significant difference between AAs group and Vehicle group.

Also, the Tyr release rate in AAs group is nearly the same levels as those in the non-exercise group whereas the Tyr release rate in AAs + P group was kept lower than that in the non-exercise group and the suppressing effect on releasing Tyr was obviously sustained in AAs + P group.

Besides, the Tyr amount was measured by Waalkes et al's fluorescent method using 1-nitroso-2-naphthol [T. P. Waalkes, S. Udenfriend, *J. Lab. Clin. Med.*, 50, 733 (1957)].

As the above, it has been confirmed that muscular proteolysis after the exercise is persistently suppressed in the present invention where the decomposition

product of whey protein was added. Besides, the same effect was confirmed in the case using WPI in place of the decomposition product of whey protein.

Example 1

Erythritol (1,375 g) and 50 g of sucrose fatty acid ester, 350 g of citric acid and 125 g of flavoring agent were added to and mixed with a granulated amino acid nutrient component mixture made up of 600 g of leucine, 300 g of isoleucine, 300 g of valine, 300 g of glutamine and 1,500 g of the decomposition product of whey protein used in Test Example 1.

Next, tablets containing 500 mg of KAAM per tablet (hereinafter referred to as tablet 1) were manufactured using a rotary type tableting machine (trade name: AP-15 type, manufactured by Hatake Ironworks) loading a plane mallet with a diameter of 13 mm.

Example 2

One where a granulated amino acid nutrient component mixture made up of 600 g of leucine, 300 g of isoleucine, 300 g of valine, 300 g of glutamine and 1,200 g of the decomposition product of whey protein used in Test Example 1, and 1,375 g of erythritol were formulated was placed in a fluidized bed granulating dryer (manufactured by Glat, WSG-5 type), a binder solution where 100 g of maltose was dissolved in 1,500 g of purified water was sprayed to yield granulation. Sucrose fatty acid ester (40 g) was added to 3,660 g of the resultant granulated dried matter to make granules for tableting.

Next, the granules were compressed and molded using the rotary type tableting machine (trade name: AP-15 type, manufactured by Hatake Ironworks) loading a plane mallet with a diameter of 15 mm to manufacture the tablets containing 450 mg of KAAM per tablet (hereinafter referred to as tablet 2). As with the above, the

tablets (hereinafter referred to as tablets 3, 4, and 5) were manufactured using hydrolysates of WPC, β -lactoglobulin and α -lactalbumin, respectively.

Example 3

Water (20 g) was added to 2.0 g of leucine, 1.0 g of isoleucine, 1.0 g of valine, 1.0 g of glutamine, 4.0 g of the decomposition product of whey protein used in Test Example 1, 13.5 g of soy bean protein, 2.5 g of chitosan, 1.5 g of arginine, 0.05 g of caffeine, 85.0 g of wheat, 50.0 g of shortening, 55.0 g of granulated sugar, and 1.5 g of baking powder, the mixture was kneaded to prepare dough and molded and then cookies were baked by the standard method.

While the present invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one of skill in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. All references cited herein are incorporated in their entirety.

This application is based on Japanese application No. 2002-350200 filed on December 2, 2002, the entire contents of which are incorporated hereinto by reference.

Industrial Applicability

The present invention provides amino acid nutrient compositions which exhibit sustained recovery effects on muscular fatigue.

CLAIMS

1. A sustained improver of muscular fatigue, which consists of leucine, isoleucine, valine, glutamine and a whey protein component.
2. A sustained improver of muscular fatigue, which comprises, as active ingredients, leucine, isoleucine, valine, glutamine and a whey protein component.
3. The improver according to claim 1 or 2, wherein the whey protein component is whey protein and/or a decomposition product of whey protein.
4. The improver according to claim 3, wherein the whey protein is at least one selected from the group consisting of a whey protein isolate, a whey protein concentrate, β -lactoglobulin, and α -lactalbumin.
5. The improver according to any one of claims 1 to 4, which comprises leucine in an amount of 10 to 30 parts by weight, isoleucine in an amount of 5 to 15 parts by weight, valine in an amount of 5 to 15 parts by weight, glutamine in an amount of 5 to 15 parts by weight, and the whey protein component in an amount of 75 to 25 weight.
6. The improver according to any one of claims 1 to 5, which comprises leucine in an amount of 20 parts by weight, isoleucine in an amount of 10 parts by weight, valine in an amount of 10 parts by weight, glutamine in an amount of 10 parts by weight, and the whey protein component in an amount of 50 parts by weight.

7. The improver according to claim 6, wherein the whey protein component is a decomposition product of whey protein.
8. A food or drink for sustained improvement of muscular fatigue, which comprises, as an active ingredients, leucine, isoleucine, valine, glutamine and a whey protein component.
9. The food or drink according to claim 8, wherein the whey protein component is whey protein and/or a decomposition product of whey protein.
10. The food or drink according to claim 9, wherein the whey protein is at least one selected from the group consisting of a whey protein isolate, a whey protein concentrate, β -lactoglobulin, and α -lactalbumin.
11. The food or drink according to any one of claims 8 to 10, which comprises leucine in an amount of 10 to 30 parts by weight, isoleucine in an amount of 5 to 15 parts by weight, valine in an amount of 5 to 15 parts by weight, glutamine in an amount of 5 to 15 parts by weight, and the whey protein component in an amount of 75 to 25 parts by weight.
12. The food or drink according to any one of claims 8 to 11, which comprises leucine in an amount of 20 parts by weight, isoleucine in an amount of 10 parts by weight, valine in an amount of 10 parts by weight, glutamine in an amount of 10 parts by weight, and the whey protein component in an amount of 50 parts by weight.
13. The or drink according to claim 12, wherein the whey protein component is a decomposition product of whey protein.

14. The use of leucine, isoleucine, valine, glutamine and a whey protein component for the manufacture of a sustained improver of muscular fatigue.

15. The use of leucine, isoleucine, valine, glutamine and a whey protein component for the manufacture of food or drink for sustained improvement of muscular fatigue.

16. A method of improving muscular fatigue sustainably, which comprises administering leucine, isoleucine, valine, glutamine and a whey protein component.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/JP 03/15429

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A23L1/305 A23L2/66 A61K38/04 A61K38/17		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A23L A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, FSTA		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 687 782 A (BRANTMAN EUGENE R) 18 August 1987 (1987-08-18) claims 1-24; example 1 ---	2-16
Y	FR 2 758 243 A (AJINOMOTO KK) 17 July 1998 (1998-07-17) claims 1-10 ---	1-16
Y	WO 99 49741 A (NESTLE SA ;BOZA JULIO (CH); BALLEVRE OLIVIER (CH); FINOT PAUL ANDR) 7 October 1999 (1999-10-07) page 1, line 31-33 page 3, line 4-13; claims 1-10 ---	1-16
A	WO 00 64283 A (WHITE PHILIP) 2 November 2000 (2000-11-02) page 11; claims 1-10 --- <div style="text-align: center;">-/--</div>	1-16
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents :		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">20 February 2004</div>		Date of mailing of the international search report <div style="text-align: center;">08/03/2004</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer <div style="text-align: center;">De Jong, E</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 03/15429

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 199632 Derwent Publications Ltd., London, GB; Class B05, AN 1996-316268 XP002271047 & JP 08 140628 A (MEIJI MILK PROD CO LTD), 4 June 1996 (1996-06-04) abstract</p> <p>----</p>	1-16
A	<p>DATABASE WPI Section Ch, Week 199641 Derwent Publications Ltd., London, GB; Class B03, AN 1996-408309 XP002271048 & JP 08 198748 A (AJINOMOTO KK), 6 August 1996 (1996-08-06) cited in the application abstract</p> <p>----</p>	1-16
A	<p>PATENT ABSTRACTS OF JAPAN vol. 010, no. 036 (C-328), 13 February 1986 (1986-02-13) & JP 60 186261 A (AJINOMOTO KK), 21 September 1985 (1985-09-21) cited in the application abstract</p> <p>----</p>	1-16
A	<p>EP 0 747 395 A (CLINTEC NUTRITION CO) 11 December 1996 (1996-12-11) claims 1-10</p> <p>----</p>	1-16
A	<p>US 5 641 531 A (LIEBRECHT JEFFERY WAYNE ET AL) 24 June 1997 (1997-06-24) claims 1-15</p> <p>----</p>	1-16
A	<p>DE 298 08 637 U (OEKOMAG NET GMBH) 16 July 1998 (1998-07-16) page 4; claims 1-10</p> <p>----</p>	1-16
A	<p>GB 2 335 134 A (STALPLEX LIMITED) 15 September 1999 (1999-09-15) page 5; claims 1-26</p> <p>-----</p>	1-16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 03/15429

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/15429

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4687782	A	18-08-1987	NONE	
FR 2758243	A	17-07-1998	JP 9023825 A FR 2758243 A1	28-01-1997 17-07-1998
WO 9949741	A	07-10-1999	AT 237957 T AU 3142099 A BR 9909234 A CA 2326148 A1 CN 1134227 B DE 69907170 D1 DK 1065947 T3 WO 9949741 A1 EP 1065947 A1 ES 2195555 T3 ID 27818 A	15-05-2003 18-10-1999 28-11-2000 07-10-1999 14-01-2004 28-05-2003 14-07-2003 07-10-1999 10-01-2001 01-12-2003 26-04-2001
WO 0064283	A	02-11-2000	AU 4280600 A WO 0064283 A1 CA 2306720 A1 EP 1176880 A1 US 6346264 B1	10-11-2000 02-11-2000 27-10-2000 06-02-2002 12-02-2002
JP 8140628	A	04-06-1996	JP 3425813 B2	14-07-2003
JP 8198748	A	06-08-1996	NONE	
JP 60186261	A	21-09-1985	JP 1762260 C JP 4058304 B	28-05-1993 17-09-1992
EP 0747395	A	11-12-1996	US 5728678 A AT 239037 T CA 2177195 A1 DE 69627748 D1 EP 0747395 A1 JP 9020678 A	17-03-1998 15-05-2003 07-12-1996 05-06-2003 11-12-1996 21-01-1997
US 5641531	A	24-06-1997	AT 234568 T AU 699318 B2 AU 6910696 A CA 2231653 A1 DE 69626833 D1 DE 69626833 T2 DK 852468 T3 EP 0852468 A1 ES 2195007 T3 JP 11512604 T NO 981380 A NZ 316793 A WO 9711614 A1	15-04-2003 03-12-1998 17-04-1997 03-04-1997 24-04-2003 24-12-2003 07-07-2003 15-07-1998 01-12-2003 02-11-1999 26-03-1998 29-06-1999 03-04-1997
DE 29808637	U	16-07-1998	DE 29808637 U1	16-07-1998
GB 2335134	A	15-09-1999	IE 980707 A1 IE 980708 A2	09-02-2000 04-10-2000